Bococizumab
Subcutaneous injection | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
PubChem SID | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C6414H9918N1722O2012S54 |
Molar mass | 145077.18 g·mol−1 |
Bococizumab (
LDL cholesterol.[3] Pfizer withdrew the drug from development in November 2016, determining that it was "not likely to provide value to patients, physicians or shareholders."[4]
Description
Bococizumab is a
LDL. LDL levels are a major risk factor for cardiovascular disease.[5]
Clinical trials
A phase 2b study of
LDL-C
at week 12.
The Phase 3 SPIRE trials were dose-finding studies and found bococizumab to significantly reduce LDL cholesterol levels, but was commonly associated with anti-drug antibodies. The development of anti-drug antibodies with bococizumab led to an attenuation in LDL lowering at 52 weeks. Wide variation in the relative reduction in cholesterol levels was additionally observed among those not developing antidrug antibodies. [6] After assessing the data, Pfizer abandoned further development of bococizumab. [7]
References
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Bococizumab" (PDF). American Medical Association.
- ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
- ^ a b "Bococizumab (RN316) Significantly Reduced LDL Cholesterol In Statin-Treated Adults With High Cholesterol In A Phase 2b Study". Archived from the original on 20 August 2019. Retrieved 29 December 2014.
- ^ "Pfizer scraps cholesterol fighter, trims profit forecast". Reuters. Nov 1, 2016.
- S2CID 2201087.
- S2CID 205101298. Retrieved 24 September 2020.
- ^ Adams, Ben (November 2016). "Pfizer dumps PCSK9 inhibitor bococizumab after finding 'no value' in drug". Fierce Biotech. Questex. Retrieved 24 September 2020.